AI assistant
SOLARA ACTIVE PHARMA SCIENCES LIMITED — Capital/Financing Update 2024
May 9, 2024
61842_rns_2024-05-09_3d9471e1-9064-4842-8a10-a10a70a45892.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Communication Address: Solara Active Pharma Sciences Limited 2nd Floor, Admin Block 27, Vandaloor Kelambakkam Road, Keelakottaiyur Village, Melakottaiyur (Post) Chennai – 600 127, India Tel: +91 44 43446700 Fax: +91 44 47406190 E-mail: [email protected] www.solara.co.in
Keelakottaiyur Village, Melakottaiyur (Post)
May 9, 2024
The BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001
The National Stock Exchange of India Limited Exchange Plaza BandraKurla Complex Sandra (E) Mumbai - 400 051
Scrip Code: 541540 Scrip Code: SOLARA
Dear Sir/ Madam,
Sub: Press Release
Please find attached Press Release titled “Solara finalizes Rights Issue terms”.
This is for your information and records.
Thanking you,
Yours Truly,
For Solara Active Pharma Sciences Limited
SUDDAPALLI Digitally signed by SUDDAPALLI MURALIKRISHNA MURALIKRISHNA Date: 2024.05.09 18:46:04 +05'30'
S. Murali Krishna Company Secretary
Encl.: As above
Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636
REGD. OFF: 201, Devavrata, Sector 17, Vashi Navi Mumbai - 400703. India/ Tel: 91-22-2789 2924 / 2789 3199 / Fax: 91-22-2789 2942
Press Release
==> picture [185 x 62] intentionally omitted <==
Solara finalizes Rights Issue terms
Issue Size of Rs. 449.95 Crores
Issue price fixed at Rs. 375/- ~ 25% discount to the Current Market Price
Chennai, May 9, 2024, Solara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE: 541540), a leading Active Pharmaceutical Ingredient / CRAMS company, today announced that the Rights Issue Committee (Committee) of the Company finalized the terms of the proposed rights issue to raise Rs. 449.95 Crores.
The Issue price approved by the Committee is Rs. 375/- per equity share of FV of Rs. 10/- each (including a premium of Rs. 365/- per equity share), which is based on the 90-day vwap average price calculated as on July 5, 2023, on which date the Rights Issue was originally approved by the Board of Directors.
The shareholders will be entitled to receive 1 (one) equity share for every 3 (three) equity shares held by them in the Company as on the record date, which is May 15, 2024.
The issue will be initially be partly paid followed by 2 calls as under:
| Call | Tentative schedule |
Amount per equity share | Funds proposed to be raised* |
|---|---|---|---|
| Application money (35%) | June 2024 | Rs. 131.25per equityshare | Rs. 157.48 Crores |
| First call(35%) | April 2025 | Rs. 131.25per equityshare | Rs. 157.48 Crores |
| Final call(30%) | April 2026 | Rs. 112.50per equityshares | Rs. 134.99 Crores |
- Assuming full subscription
The Promoters have committed to subscribe to their portion of the entitlement.
The issue is scheduled to open on May 28, 2024 and will close on June 11, 2024.
Choice Capital Advisors Private Limited are the Lead Managers to the Issue.
About Solara
Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA), headquartered in Bengaluru, India, offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising six globally compliant API facilities, with approvals including the USFDA, EU GMP, and PMDA in Japan.
| Investor / Analyst contact | Statutory and corporate affairs |
|---|---|
| Abhishek Singhal | Murali Krishna S |
| [email protected] | Raghavan. V |
| +91 99877 66968 | [email protected] |
Disclaimer: Certain statements in this document are not historical facts and are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.